AZ and Takeda join in $400m Parkinson’s therapy deal
AstraZeneca and Takeda have signed a deal to mutually develop and commercialise an experimental therapy for Parkinson’s disease. The companies will work together to advance AZ’ MEDI1341, an antibody to alpha-synuclein, an aggregation-prone protein that contributes to the development of the condition.